20 December 2024: AbbVie recently announced positive topline results from its pivotal Phase III TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy in early Parkinson’s disease (PD). Tavapadon, the first and only D1/D5 partial agonist in the dopamine agonist class, is under investigation as a once-daily treatment for PD. The trial met both its…
Category: Parkinson’s Disease
Hearing loss associated with PD
A recent study using electronic health records from over 3 million U.S. veterans has identified hearing loss as an independent risk factor for developing Parkinson’s disease (PD). Published in JAMA Neurology, the research revealed that hearing loss increases PD risk even when adjusting for factors like age, head trauma, and prodromal disorders. Researchers suggested that…
AI detects voice changes in PD
26 November 2024: Algorithms that can detect subtle voice changes in PD are emerging as a potential new diagnostic tool for Parkinson’s disease, according to researchers from Iraq and Australia. Speech impairments are often the first indicators of Parkinson’s disease, but traditional diagnostic methods are often complex and slow, delaying early detection. Researchers from Middle Technical…
Reducing dysbiosis and gastrointestinal issues in PD
Parkinson’s drug changes the gut microbiome for the worse due to iron deficiency 21 November 2024: In a new study, conducted within the framework of the FWF-funded Cluster of Excellence “Microbiomes drive Planetary Health”, scientists from the University of Vienna, in collaboration with the University of Southampton, Aalborg University and Boston University, have revealed that…
Phase 2 LRRK2 inhibitor trial in early PD
19 November, 2024: Neuron23 Inc. has announced the Phase 2 NEULARK clinical trial of NEU-411, a brain-penetrant LRRK2 inhibitor, targeting early-stage Parkinson’s disease (PD). The trial employs precision medicine strategies, focusing on individuals with LRRK2-driven PD, who may represent up to 30% of the PD population. This population includes those with familial LRRK2 mutations and…
2024 Tom Isaacs Award honours Parkinson’s expert Professor Oliver Bandmann
Cure Parkinson’s and Van Andel Institute (VAI) have announced Professor Oliver Bandmann as the winner of the 2024 Tom Isaacs Award, which honours researchers who closely collaborate with the Parkinson’s community. The award was virtually presented to Professor Bandmann as part of the annual Grand Challenges in Parkinson’s Disease symposium and parallel Rallying to the…
Parkinson’s disease therapy Vyalev gets FDA approval
AbbVie announced on 17th October that the US Food and Drug Administration (FDA) has approved VYALEV™ (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). The treatment is approved in 35 countries. The approval was supported by…
Ophthalmic acid – its role in motor function control
Brain molecule reverses movement deficits of Parkinson’s, offering new therapeutic target October 4th 2024: A research team from the University of California, Irvine is the first to reveal that a molecule in the brain – ophthalmic acid – unexpectedly acts like a neurotransmitter similar to dopamine in regulating motor function, offering a new therapeutic target…
Cannabis-based medicine for neurodegenerative diseases
Avextra announces the approval of NEUROBIS by the Italian Medicines Agency: A Phase II clinical trial Avextra AG, a European manufacturer and developer of Cannabis-based medicines located in Germany, has announced that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to…
